For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 138,349 | |||
| General and administrative | 30,734 | |||
| Total operating expenses | 169,083 | |||
| Loss from operations | -169,083 | |||
| Interest income | 5,518 | |||
| Other income, net | 2,413 | |||
| Total other income, net | 7,931 | |||
| Net loss | -161,152 | |||
| Basic EPS | -18.56 | |||
| Diluted EPS | -18.56 | |||
| Basic Average Shares | 8,680,741 | |||
| Diluted Average Shares | 8,680,741 | |||
MapLight Therapeutics, Inc. (MPLT)
MapLight Therapeutics, Inc. (MPLT)